US FDA approves Jazz Pharma’s Ziihera to treat adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer: Dublin Friday, November 22, 2024, 1 ...

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.

Hong Joo Kim; Kyu Taek Lee; Seung Hoon Kim; Jong Kyun Lee; Jae Hoon Lim; Seung Woon Paik; Jong Chul Rhee Extrahepatic cholangiocarcinoma is usually evident on cholangiogram, but the intrahepatic ...

NAFLD is a multisystem disease where systemic insulin resistance and related metabolic dysfunction play a pathogenic role in the development of NAFLD and its most relevant liver-related morbidities ...

Delcath's Q3 sales hit $10 million, unlocking $25 million for Phase 2 trials. Click here to find out my analysis of DCTH ...

Previous data had leaned towards an increased incidence of intrahepatic CCAs worldwide; however, this has been proved to be secondary to a misclassification of Klatskin's tumors as intrahepatic CCAs.

GlobeNewswire, Health, Pharmaceuticals & Biotechnology, Product / Services Announcement | Ziihera is the first and only dual HER2-targeted bispecific ...

In rare diseases, rare mutations have long been thought of as the only contributor. Genetic analyses of people with such conditions now suggest that the effects of common genetic variants can ...